2003 - Verona - Italy

2003 - Verona - Italy

Thursday June 12
08:00-08:45 Registration and coffee
08:45-09:00 Welcome and Introduction
  Oral session I Estimating parameter uncertainty chair: Niclas Jonsson
09:00-09:30 Ken Kowalski Evaluation of a Random Sparse Sampling Design: An Assessment of Power and Bias Using Simulation(Presentation Slides, 121Kb)

Bill Gillespie

Case Study in the Use of Bayesian Hierarchical Modeling and Simulation for Design and Analysis of a Clinical Trial (Presentation Slides, 350Kb)
10:00-11:00 Coffee break, Poster and Software session I
  Posters in Group I are accompanied by their presenter (see below)
  Oral session II Physiological and disease models chair: Mats Karlsson
11:00-11:30 Katarina Jelic Obesity and Insulin Resistance: A Fat Link (Presentation Slides, 1.76Mb)
11:30-11:50 Fredrik Jonsson A pharmacodynamic model for Scandinavian Stroke Scale data (Presentation Slides, 150Kb)
11:50-12:10 Maria Rosario A PK-PD-disease model to support the design of clinical trials of drugs for the treatment of HIV
12:10-12:30 Joost DeJongh Disease progression modelling; application of population analysis to distinguish between symptomatic and protective treatment effects
12:30-14:00 Lunch
  Oral session III   chair: Janet Wade
14:00-14:20 Christoffer Wenzel Tornøe Population Pharmacokinetic Modelling of a Subcutaneous Depot for GnRH Antagonist Degarelix (Presentation Slides, 934Kb)
14:20-14:40 Chuanpu Hu A Modeling Approach to Assessing Bioequivalence (BE) with Presence of Sparsely Sampled Subjects (Presentation Slides, 218Kb)
14:40-15:00 Marta Valle Absorption and plasma kinetics of multiple high oral doses of glucose: influence of glibenclamide
15:00-16:00 Tea, Posters and Software
  Oral session IV   chair: Ferdie Rombout
16:00-16:20 Thomas Kerbusch Assessment of the in vivo relative potency of the hydroxylated metabolite of darifenacin for the reduction of salivary flow using a population pharmacokinetic-pharmacodynamic meta-analysis
16:20-16:40 Bernard Vrijens Dose-Timing Information Improves The Clinical Explanatory Power Of Data On Patient Adherence To Antiretroviral Drug Regimens (Presentation Slides, 558Kb)
16:40-17:00 Joachim Stangier Population pharmacokinetics/-dynamics of dabigatran, the active form of the new oral direct thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing hip replacement (Presentation Slides, 1.04Mb)
17:00-17:05 Leon Aarons/ Malcolm Rowland Journal of Pharmacokinetics and Pharmacodynamics
17:05-17:30 Planning of future PAGE meetings, preview PAGE 2004, Uppsala, Sweden
19:00-24:00 Social Evening  
Friday June 13
  Oral session V Distributed computing chair: Pascal Girard
09:00-09:30 Mark Sale Applications of Distributed computing in Drug development (Presentation Slides, 251Kb)
09:30-10:00 Lars Lindbom Distributed computing under Linux (Presentation Slides, 373Kb)
10:00-11:00 Coffee, Poster and Software session II
  Posters in Group II are accompanied by their presenter (see below)
  Tutorial Physiological and disease models chair: Leon Aarons
11:00-11:40 James Bassingthwaighte

Developing Integrated Cell Systems

  Oral session VI Physiological and disease models chair: Oscar Della Pasqua
11:40-12:10 Daren Austin/Roy Anderson

Patient adherence and the evolution of resistance to anti-viral agents

12:10-12:30 Naoto Hayashi A Mechanism-Based PK/PD Model Predicts the Time-Course of Hematological responses for Epoetin beta (Presentation Slides, 777Kb)
12:30-14:00 Lunch
  Oral session VII Clinical chair: Mick Looby
14:00-14:20 Emmanuelle Comets Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients (Presentation Slides, 379Kb)
14:20-14:40 Raymond Miller Pregabalin Exposure-Adverse Event Analysis in Patients With Neuropathic Pain, Generalized Anxiety Disorder, or Partial Seizures (Presentation Slides, 1.44Mb)
14:40-15:00 Georg Hempel Population Pharmacokinetics of Intravenous Busulfan in Children (Presentation Slides, 401Kb)
15:00-16:00 Tea, Posters and Software
  Oral session VIII   chair: France Mentré
16:00-16:20 Marc Lavielle Maximum likelihood estimation in nonlinear mixed effects models (Presentation Slides, 851Kb)
16:20-16:40 Gianluca Nucci Design and power PK/PD experiments using very sparse data (Presentation Slides, 306Kb)
16:40-17:00 Stephen Duffull Estimating population pharmacokinetic parameters when dose and dose-time are not known accurately
17:00-17:05 Concluding remarks

Posters Thursday (group I)

Alexia Blesius Potential consequences of drug non-compliance on the therapeutic / iatrogenic effects of oral anticoagulant therapy : an in silico study.
Christine Garnett Clinical Trial Simulation of the Dose-Response Relationship of a Direct Thrombin Inhibitor, Dabigatran Etexilate, in Hip Replacement Patients
Jan Freijer Modelling of drug absorption as a transport-limited process
Nick Holford Implications of Including and Excluding Correlation of Random Effects in Hierarchical Mixed Effects Pharmacokinetic Models
Robert Leary Improved Computational Methods for Statistically Consistent and Efficient PK/PD Population Analysis
Tim Waterhouse Optimal Designs For Parameter Estimation And Model Discrimination
Vladimir Piotrovsky Population PK-PD analysis of cardiovascular effects of non-cardiovascular drugs with the emphasis on QT prolongation
Andreas Groth Markedly different predictions about insulin PharmacoDynamic (PD) measurement feasibility in healthy subjects from recently proposed IntraVenousGlucoseToleranceTest (IVGTT)-based insulin-glucose models
Annick Rousseau Pharmacokinetics of cyclosporine in lung transplant patients with and without cystic fibrosis. A NONMEM analysis.
Bruce Green Development of a dosing strategy for enoxaparin in patients with renal impairment using a population pharmacokinetic approach
Candice Jamois Pharmacokinetic analysis of paclitaxel administered per os in Swiss mice after a pre-treatment with recombinant interleukin-2 (rIL2).
Chantal Le Guellec Population pharmacokinetics of cisapride in preterm and term neonates
Christoffer Wenzel Tornøe Non-Linear Mixed-Effects Models in NLME with Differential Equations
Daniel Jonker Population pharmacodynamic analysis of the anticonvulsant effects of tiagabine and lamotrigine in combination
David Reith Comparison of NONMEM with the Two-Stage approach for obtaining population means of the pharmacokinetic parameters of fluoxetine
Gianluca Nucci Comparison of alternative models for the analysis of drug disposition profiles showing enterohepatic circulation using a population approach
Gudrun Wuerthwein Population Pharmacokinetics of Amphotericin B Lipid Complex in Neonates
Hugo Maas A hidden markov model for characterizing the anti-migraine action of triptans
Hussain Mulla Population Pharmacokinetics of Vancomycin during Extra Corporeal Membrane Oxygenation (ECMO)
In-Sun Nam Multiple Imputation of Serum Creatinine
Ivelina Gueorguieva D-Optimal Design for Multivariate Response: Prospective Planning of a Beta-blocker Study in Rat Involving Cassette Dosing
Jakob Ribbing Power, Selection Bias And Predictive Performance Of The Population Pharmacokinetic Covariate Model
Joachim Stangier Population pharmacodynamic analysis of dabigatran, the active form of the new oral direct thrombin inhibitor dabigatran etexilate (BIBR 1048), on the prolongation of aPTT and ECT in orthopaedic patients.
Joachim Stangier Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR1048) in patients undergoing primary elective total hip replacement surgery.
Karl Brendel Population pharmacokinetic analysis of indinavir in HIV-patients treated with a stable antiretroviral therapy
Kayode Ogungbenro Sample Size Calculation based on Confidence interval for Pharmacokinetic Studies
Lorraine Ralph Bayesian Estimation of Epirubicin Clearance by Limited Sampling
Milly de Jonge Integrated population pharmacokinetic model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction.
Pascal Chanu Pharmacokinetic model for vancomycin performed with sparse data on neonates
Philip Lowe Probabilistic Risk Assessment Using Integrated Preclinical-Clinical PK/PD Modelling in NONMEM
Quyen Ho-Nguyen Population pharmacokinetic modelling of Emfilermin in healthy postmenopausal women and in women undergoing Embryo Tranfer (ET)
Robert Bies Comparing binary tree and automated machine learning covariate search strategies
Sophie Gisbert Incorporating Variability in WBPBPK Models: Application to Three Benzodiazepines with Extrapolation from Rat to Man
Sophie Glatt Population Pharmacokinetics of onercept in healthy subjects.
Tomoo Funaki Computer-Assisted Trial Design (CATD) for PEG-IFN with Using PD Marker to Predict Efficacy
Xavière Panhard Evaluation by simulation of tests based on non-linear mixed-effects models in interaction and bioequivalence cross-over trials

Posters Friday (group II)

Alessandra Bertoldo Population approaches for quantitative PET imaging
An Vermeulen
Modeling the longitudinal concentration-response data after i.m. administration of Risperdal CONSTATM in psychotic patients of different phenotypes
Andrew Hooker
Simultaneous Population D-Optimal Designs of Pharmacokinetic-Pharmacodynamic Experiments
Ann Allen
Meta analysis and clinical trial simulation in drug development.
Annabelle Lemenuel-Diot
Comparison between Gauss Hermite quadrature and NONMEM on the ability to detect subpopulations
Brian Mc Hugh
Population Pharmacodynamic Analysis of Glucose and Insulin levels Evaluated with a Hot Glucose Minimal Model, a Total Glucose Minimal Model, and an Insulin Minimal Model
Delphine Martin
Combined-PK-Analysis of a new compound exhibiting highly variable plasma profiles due to first pass metabolism
Dymphy Huntjens
Modelling of biomarker response of naproxen in rats and humans
Ekaterina Gibiansky
Bispectral Index of AQUAVAN™-Derived Propofol: Population PK/PD Modeling and Application to an Effect - Controlled Trial
Eugene Cox
A Population Pharmacokinetic-Pharmacodynamic Model For Count Data: Application to the Effect of Atosiban on Uterine Activity in Preterm Labor Patients
Italo Poggesi
A Bayesian approach to non-parametric AUC estimation in population studies
Italo Poggesi
Application of population approaches in pharmaco-toxicological studies
Jagadeesh Aluri
Cilomilast (Ariflo®): Population pharmacokinetic modeling and validation in COPD patients.
Karin Tunblad
An integrated model for data from a microdialysis experiment
Kristin Karlsson
Randomized dose ranging trials; assessment of statistical power for various design and analysis strategies
Leonid Gibiansky
Simultaneous Population Pharmacokinetic Model of AQUAVAN™ and AQUAVAN™-Derived Propofol
Line Labbe
A Markov Model For The Effect Of Covariates Including Drug Adherence On Longitudinal Viral Response In HIV Patients
Maria Garrido
Population pharmacokinetic/pharmacodynamic modelling of the haematological effects of the new anticancer drug diflomotecan: A combined analysis from the first two phase I studies
Marie Sandström
Population Analysis of the Pharmacokinetics and the Haematological Toxicity of the Fluorouracil-Epirubicin-Cyclophosphamide Regimen in Breast Cancer Patients
Miren Zamacona
Influence of study design and interindividual variability on In Vitro - In Vivo Correlation evaluation
Monica Rodriguez Calvo
Influence of high levels of alpha-1-acid glycoprotein in the pharmacokinetics and the analgesic effect of methadone in the rat: A population approach
Nerea Leal Egiluz
Altered effect and pharmacokinetics of propofol in rats with experimental diabetes mellitus
Nils Ove Hoem
Establishing a tool for individualised dosing of gabapentin - The use of a non-parametric population kinetics model in the MM-USCPACK software, a new tool for clinical dosage optimization.
Pascal Girard Evaluation Of An Osteoporosis Biomarker Model For Simulation Using Posterior Predictive Check Technique
Salhi Sabrina
Population Whole Body Physiologically based Pharmacokinetic/Pharmacodynamic modelling in drug development: Impact of input parameters variability and incertainty on pharmacodynamic response
Sandra Visser
Modelling of the tolerance, rebound and carry-over phenomena observed in clomethiazole-induced hypothermic effects in rats.
Sherwin Sy
Pharmacodynamic drug interaction of roxifiban during CYP induction and inhibition
Sophie Callies
Pharmacokinetics of Daunorubicin and its metabolite Daunorubicinol in the absence and presence of a potent P-gp inhibitor, Zosuquidar.3HCl (LY335979).
Stefano Zamuner
Impact of slow receptor binding kinetics and change in Cerebral Blood Flow in receptor occupancy estimation with PET experiments. A simulation study
Sunny Chapel
Modeling & Simulation Approach to Discriminate True Food Effects: Comparison with Standard Noncompartmental Methods
Ulrika Simonsson
Population PK/PD Modeling of Testosterone (T), LH and Dihydrotestosterone (DHT) Response to Single SC Degarelix in Male Volunteers
Xuejun Chen
Comparison of different approaches for the analysis of drug exhibiting nonlinearity of Cmax to increasing doses
Yann Bourhis Population Pharmacokinetic Study of Fotemustine
Yann Merle
Nonparametric population analysis of stavudine pharmacokinetic data in neonates, infants, children and adults